Patents Assigned to UPPTHERA, INC.
-
Publication number: 20260226071Abstract: Novel 2,4-Dianilinopyrimidine-based Aurora-A kinase (AURKA) degraders are disclosed. The present AURKA degraders are proteolysis targeting chimeras (PROTACs) that recruit AURKA protein into optimized CRBN E3 ubiquitin ligase via linkers. The compounds may induce selective AURKA degradation and may be utilized for the treatment of cancer.Type: ApplicationFiled: January 17, 2024Publication date: August 6, 2026Applicant: UPPTHERA, INC.Inventors: Soo Hee Ryu, Seong Hoon Kim, Han Kyu Lee, Ha Na Jeong
-
Publication number: 20260199367Abstract: Novel dihydropteridone or pyrimidodiazepinone derivative based PLK1 degraders are disclosed. The present PLK1 degraders are proteolysis targeting chimeras (PROTACs) that recruit PLK1 protein into CRBN E3 ubiquitin ligase via optimized rigid linkers. The compounds may induce PLK1 degradation with improved drug properties and may be utilized for example, as a payload of antibody-drug conjugated (ADC) for the treatment of cancer.Type: ApplicationFiled: November 29, 2023Publication date: July 16, 2026Applicant: UPPTHERA, INC.Inventors: Soo Hee Ryu, Seong Hoon Kim, Jun Kyu Lee, Keum Young Kang, Gibbeum Lee, Sang Youn Kim, Solhee Noh
-
Publication number: 20250114460Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: ApplicationFiled: August 10, 2022Publication date: April 10, 2025Applicant: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Publication number: 20250101025Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: ApplicationFiled: August 10, 2022Publication date: March 27, 2025Applicant: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Publication number: 20240316054Abstract: The present invention relates to a PLK1 protein degradation inducing compound, a preparation method thereof, and a use thereof. Compounds of the present invention target PLK1 and BRD4 to degrade PLK1, and decompose BRD4 to a suitable level within the scope of causing no side effects, and thus can be very advantageously used for prevention or treatment of cancer or neural disease.Type: ApplicationFiled: June 29, 2022Publication date: September 26, 2024Applicant: UPPTHERA, INC.Inventors: Hye Guk Ryu, Keum Young Kang, Im Suk Min, Seong Hoon Kim
-
Patent number: 11939334Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: GrantFiled: August 10, 2022Date of Patent: March 26, 2024Assignee: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Patent number: 11912710Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: GrantFiled: August 10, 2022Date of Patent: February 27, 2024Assignee: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Patent number: 11833208Abstract: The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.Type: GrantFiled: March 27, 2021Date of Patent: December 5, 2023Assignee: UPPTHERA, INC.Inventors: Si Woo Choi, Soo Hee Ryu, Ji Hoon Ryu, San Ha Son, Hwa Jin Lee, Seong Hoon Kim, Boas Nam, Im Suk Min, Hye Guk Ryu, Keum Young Kang
-
Publication number: 20230242541Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: ApplicationFiled: August 10, 2022Publication date: August 3, 2023Applicant: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Publication number: 20230219966Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: ApplicationFiled: August 10, 2022Publication date: July 13, 2023Applicant: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
